Effects of SLCO1B1 Polymorphisms on Plasma Estrogen Concentrations in Women with Breast Cancer Receiving Aromatase Inhibitors Exemestane and Letrozole

References

• Howlader N , AltekruseSF , LiCIet al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI J. Natl Cancer Inst.106(5), pii:dju055 (2014).
   Web of Science ®Google Scholar
• Geisler J , HaynesB , AnkerG , DowsettM , LønningPE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol.20(3), 751–757 (2002).
   PubMed Web of Science ®Google Scholar
• Geisler J , KingN , AnkerGet al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients . Clin. Cancer Res.4(9), 2089–2093 (1998).
   PubMed Web of Science ®Google Scholar
• Cuzick J , SestakI , BaumMet al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol.11(12), 1135–1141 (2010).
   PubMed Web of Science ®Google Scholar
• Regan MM , NevenP , Giobbie-HurderAet al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol.12(12), 1101–1108 (2011).
   PubMed Web of Science ®Google Scholar
• Smith I , YardleyD , BurrisHet al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized Phase III femara versus anastrozole clinical evaluation (FACE) trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.35(10), 1041–1048 (2017).
   PubMed Web of Science ®Google Scholar
• Goss PE , IngleJN , PritchardKIet al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 – a randomized controlled Phase III trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.31(11), 1398–1404 (2013).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group . Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet386(10001), 1341–1352 (2015).
   PubMed Web of Science ®Google Scholar
• Miller WR , LarionovAA. Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res.14(1), 201 (2012).
   PubMed Web of Science ®Google Scholar
• Ingle JN , BuzdarAU , SchaidDJet al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res.70(8), 3278–3286 (2010).
   PubMed Web of Science ®Google Scholar
• Hertz DL , HenryNL , RaeJM. Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients. Pharmacogenomics18(5), 481–499 (2017).
   PubMed Web of Science ®Google Scholar
• Kalliokoski A , NiemiM. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol.158(3), 693–705 (2009).
   PubMed Web of Science ®Google Scholar
• Gregory BJ , ChenSM , MurphyMA , AtchleyDH , KamdemLK. Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy postmenopausal female volunteers. J. Clin. Pharm. Ther.42(5), 547–553 (2017).
   PubMed Web of Science ®Google Scholar
• Dudenkov TM , IngleJN , BuzdarAUet al. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway . Breast Cancer Res. Treat.164(1), 189–199 (2017).
   PubMed Web of Science ®Google Scholar
• Henry NL , GilesJT , AngDet al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res. Treat.111(2), 365–372 (2008).
   PubMed Web of Science ®Google Scholar
• Desta Z , KreutzY , NguyenATet al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin. Pharmacol. Ther.90(5), 693–700 (2011).
   PubMed Web of Science ®Google Scholar
• Robarge JD , DestaZ , NguyenATet al. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res. Treat.161(3), 453–461 (2017).
   PubMed Web of Science ®Google Scholar
• Hertz DL , SpethKA , KidwellKM et al. Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in postmenopausal breast cancer patients. Breast Cancer Res. Treat.165(3), 659–668 (2017).
   PubMed Web of Science ®Google Scholar
• Henry NL , AzzouzF , DestaZet al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J. Clin. Oncol.30(9), 936–942 (2012).
   PubMed Web of Science ®Google Scholar
• Pasqualini JR , ChetriteG , BlackerCet al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab.81(4), 1460–1464 (1996).
   PubMed Web of Science ®Google Scholar
• Ramsey LB , MoncrieffeH , SmithCNet al. Association of SLCO1B1*14 allele with poor response to methotrexate in juvenile idiopathic arthritis patients. ACR Open Rheumatol.1, 58–62 (2019).
   PubMedGoogle Scholar
• Wang L , EllsworthKA , MoonIet al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res.70(1), 319–328 (2010).
   PubMed Web of Science ®Google Scholar
• Ghimenti C , Mello-GrandM , GrossoEet al. Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy. Exp. Ther. Med.5(3), 902–906 (2013).
   PubMed Web of Science ®Google Scholar
• Fuhrman BJ , SchairerC , GailMHet al. Estrogen metabolism and risk of breast cancer in postmenopausal women. JNCI J. Natl Cancer Inst.104(4), 326–339 (2012).
   Web of Science ®Google Scholar
• Key T , ApplebyP , BarnesI , ReevesG. Endogenous Hormones and Breast Cancer Collaborative Group.Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl Cancer Inst.94(8), 606–616 (2002).
   PubMed Web of Science ®Google Scholar
• Brown SB , HankinsonSE. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids99, 8–10 (2015).
   PubMed Web of Science ®Google Scholar
• Smiley DA , KhalilRA. Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr. Med. Chem.16(15), 1863–1887 (2009).
   PubMed Web of Science ®Google Scholar
• Wang X , PankratzVS , FredericksenZet al. Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum. Mol. Genet.19(14), 2886–2897 (2010).
   PubMed Web of Science ®Google Scholar
• Lønning PE . The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann. Oncol.22(3), 503–514 (2011).
   PubMed Web of Science ®Google Scholar
• Borrie AE , RoseRV , ChoiY-Het al. Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Res. Treat.172(2), 371–379 (2018).
   PubMed Web of Science ®Google Scholar
• Kadakia KC , KidwellKM , SeewaldNJet al. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res. Treat.164(2), 411–419 (2017).
   PubMed Web of Science ®Google Scholar
• Shitara Y . Clinical importance of OATP1B1 and OATP1B3 in drug–drug interactions. Drug Metab. Pharmacokinet.26(3), 220–227 (2011).
   PubMed Web of Science ®Google Scholar